Liposomal nystatin (L-NYS) in therapy of pulmonary aspergillosis refractory to conventional amphotericin B in cancer patients.
Krupova
Y
Y
Mistrik
M
M
Bojtarova
E
E
Sejnova
D
D
Ilavska
I
I
Krcmery
V
V
D000293:Adolescent; D000328:Adult; D000666:Amphotericin B / Q000627:therapeutic use; D000935:Antifungal Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D001228:Aspergillosis / Q000188:drug therapy*; D002648:Child; D005260:Female; D015725:Fluconazole / Q000627:therapeutic use; D006801:Humans; D008081:Liposomes; D008172:Lung Diseases, Fungal / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications*; D009761:Nystatin / Q000008:administration & dosage* / Q000009:adverse effects; D017211:Treatment Failure; D016896:Treatment Outcome
D000935:Antifungal Agents; D008081:Liposomes; D009761:Nystatin; D000666:Amphotericin B; D015725:Fluconazole